Clinical Trials Logo

Filter by:
NCT ID: NCT02616159 Completed - Glycemic Response Clinical Trials

Effect of Oatmeal Varieties on Glycemic and Insulinemic Responses in Healthy Individuals

Start date: November 2015
Phase: N/A
Study type: Interventional

The objectives of this study are to compare the glycemic and insulinemic responses over 3 hours elicited by 3 oatmeal varieties compared to each other and to controls of ready to eat and hot cereals.

NCT ID: NCT02615821 Completed - Exercise Clinical Trials

Mental Contrasting Physical Activity Study

Start date: January 2015
Phase: N/A
Study type: Interventional

Given the numerous physical and psychological benefits of engaging in regular physical activity (Biddle & Ekkekakis, 2005; Warburton et al., 2007) and the decrease in students' physical activity levels during the transition from high school to university (Bray & Born, 2010) it is important for researchers to develop time-and-cost-effective interventions to prevent this drop in physical activity. Intervention research shows mental contrasting (a goal setting strategy) can be taught in a cost-and-time-effective way in order to increase physical activity (Oettingen, 2012). Researchers have also found that individuals who consider the emotional effects of physical activity are more likely to be physically active than those who consider the health-related effects (Rhodes et al., 2009). The purpose of this research is to combine these two approaches to develop and evaluate a novel mental contrasting intervention to increase physical activity among a sample of undergraduate students.

NCT ID: NCT02615132 Completed - Stroke Clinical Trials

TeleRehab for Stroke Patients Using Mobile Technology

Start date: December 2015
Phase: N/A
Study type: Interventional

Post-stroke communication deficits (PSCD) are a common symptom of patients having sustained a stroke. These deficits include difficulty to produce or understand language, motor speech disorders and cognitive-communication disorders. It is estimated that approximately 40% of stroke survivors will have communication disorders post stroke. In this randomized controlled study, the investigators' objective is to test the value of providing a mobile platform-based Speech Language Therapy (SLT) program to patients discharged from an acute care hospital with stroke and PSCD and awaiting outpatient rehab services versus standard of care treatment. The investigators will offer iPad-based SLT/standard of treatment to a convenience sample of 20 patients with post-stroke communication deficits. The primary outcome will be feasibility (recruitment rate, adherence rate, retention rate, and protocol deviations), and the secondary outcome will be improvement in PSCD.

NCT ID: NCT02615067 Completed - Prostate Cancer Clinical Trials

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer

proSPECT-AS
Start date: December 2015
Phase: Phase 3
Study type: Interventional

99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason Score of ≤ 3+4 severity who are candidates for active surveillance and are undergoing voluntary radical prostatectomy (RP) [Cohort A] or routine prostate biopsy [Cohort B]. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 SPECT/CT imaging to correctly identify subjects with previously unknown clinically significant prostate cancer.

NCT ID: NCT02614794 Completed - Clinical trials for HER2 Positive Breast Cancer

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

HER2CLIMB
Start date: January 28, 2016
Phase: Phase 2
Study type: Interventional

This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. All patients in the study will get capecitabine and trastuzumab, two drugs that are often used to treat this cancer. There are two parts to this study. The first part of the study is already complete. Patients were randomly assigned to get either tucatinib or placebo (a pill with no medicine). Since this part was "blinded," neither patients nor their doctors knew whether a patient got tucatinib or placebo. The second part of the study is called the Unblinded Phase. In this part of the study, participants and their doctors know which drugs are being given. Participants who used to get or are currently getting placebo may be able to start taking tucatinib instead. Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills two times every day. They will swallow capecitabine pills two times a day during the first two weeks of each cycle. Patients will get trastuzumab injections from the study site staff on the first day of every cycle.

NCT ID: NCT02614482 Completed - Overactive Bladder Clinical Trials

Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.

FOXY2015
Start date: October 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long term tolerability of Fesoterodine and its efficacy for overactive bladder syndrome in children.

NCT ID: NCT02614287 Completed - Migraine Clinical Trials

A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

Start date: November 30, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the longer term safety of the study drug known as galcanezumab in participants with episodic or chronic migraine.

NCT ID: NCT02614261 Completed - Chronic Migraine Clinical Trials

Evaluation of Galcanezumab in the Prevention of Chronic Migraine

REGAIN
Start date: November 30, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.

NCT ID: NCT02614183 Completed - Migraine Clinical Trials

Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study

EVOLVE-1
Start date: November 30, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.

NCT ID: NCT02614066 Completed - Clinical trials for Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

ZUMA-3
Start date: March 7, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).